目的:研究程序性死亡蛋白-1(programmed death protein-1，PD-1)抑制剂(信迪利单抗)联合TS方案(紫杉醇+替吉奥)治疗进展期胃癌腹膜腔转移患者的临床效果及安全性。方法:回顾性分析2019年8月-2021年12月本院收治的80例进展期胃癌腹膜腔转移患者的临床资料，将其根据治疗方式分为对照组和观察组，每组各40例。对照组采用TS方案治疗，观察组患者在对照组的基础上再给予PD-1抑制剂治疗。比较两组患者的临床疗效、治疗前后肿瘤标志物[糖类抗原(CA199)、癌胚抗原(CEA)]水平。观察治疗前、治疗1、2个疗程后的病灶直径水平，对比两组患者治疗期间的不良反应发生情况。治疗结束后对两组患者随访1年，观察随访期间的生存情况。结果:观察组总有效率高于对照组(87。50％vs 65。00％，P＜0。05)。治疗后，两组患者的血清CA199、CEA水平均低于治疗前(P＜0。05)，且观察组患者的血清CA199、CEA水平低于对照组(P＜0。05)。与治疗前比较，治疗1、2个疗程后两组患者的病灶直径水平均降低(P＜0。05)，观察组患者治疗1、2个疗程后病灶直径水平低于对照组(P＜0。05)。观察组患者的胃肠道反应、白细胞减少、贫血、甲状腺功能减退、手足综合征等不良反应发生率与对照组比较，差异无统计学意义(P＞0。05)。观察组患者的生存率高于对照组(55。00％vs 30。00％，P=0。024)。结论:PD-1抑制剂联合TS方案可明显提高进展期胃癌腹膜腔转移患者的临床疗效，下调肿瘤标志物水平，缩小病灶，更有利于提高的患者生存率且安全性佳。
Clinical efficacy and safety of programmed death protein-1 inhibitor combined with TS regimen in the treatment of peritoneal metastasis of advanced gastric cancer
Objective:To study the clinical efficacy and safety of programmed death protein-1(PD-1)inhibitor(Xindilimab)combined with TS regimen(taxol+gimeracil and oteracil porassium capsules)in the treatment of peritoneal metastasis of advanced gastric cancer.Methods:Clinical data of 80 patients with advanced gastric cancer with peritoneal metastasis admitted to our hospital from August 2019 to December 2021 were retrospectively ana-lyzed,and they were divided into control group and observation group according to treatment methods,with 40 cases in each group.The control group was treated with TS regimen,and the patients in the observation group were treated with PD-1 inhibitor on the basis of the control group.The clinical efficacy,levels of tumor markers[carbohydrate antigen(CA199),carcinoembryonic antigen(CEA)]before and after treatment were compared be-tween the two groups.The diameter of the lesion was observed before and after 1 and 2 courses of treatment.The adverse reactions of the two groups during treatment were compared.After treatment,the patients in the two groups were followed up for 1 year to observe their survival during the follow-up period.Results:The total effec-tive rate of the observation group was higher than that of the control group(87.50％vs 65.00％,P＜0.05).Af-ter treatment,the levels of serum CA199 and CEA in the two groups were lower than those before treatment(P＜0.05),and the levels of serum CA199 and CEA in the observation group were lower than those in the control group(P＜0.05).Compared with before treatment,the lesion diameter of the two groups decreased after one course of treatment and two courses of treatment(P＜0.05).After one course of treatment and two courses of treatment,the lesion diameter in the observation group was lower than that in the control group(P＜0.05).There was no significant difference between the observation group and the control group in the incidence of gastro-intestinal reactions,leukopenia,anemia,hypothyroidism,hand foot syndrome and other adverse reactions(P＞0.05).The survival rate in the observation group was higher than that in the control group(55.00％vs 30.00％,P=0.024).Conclusion:PD-1 inhibitor combined with TS regimen can significantly improve the clinical efficacy of patients with peritoneal metastasis of advanced gastric cancer,reduce the level of tumor markers,shrink the fo-cus,and is more conducive to improving the survival rate of patients with good safety.
programmed death protein-1 inhibitortaxolgimeracil and oteracil porassium capsulesgastric cancerperitoneal cavity metastasis
万方数据
维普
